Literature DB >> 33527731

Design, Synthesis, and Structure-Activity Relationship Study of Pyrazolones as Potent Inhibitors of Pancreatic Lipase.

Jing Zhang1, Yang Yang2, Xing-Kai Qian1, Pei-Fang Song1, Yi-Shu Zhao1, Xiao-Qing Guan1, Li-Wei Zou1, Xiaoze Bao2, Hong Wang2.   

Abstract

Pancreatic lipase (PL), a key target for the prevention and treatment of obesity, plays crucial roles in the hydrolysis and absorption of in dietary fat. In this study, a series of pyrazolones was synthesized, and their inhibitory effects against PL were assayed by using 4-methylumbelliferyl oleate (4-MUO) as optical substrate for PL. Comprehensive structure-activity relationship analysis of these pyrazolones led us to design and synthesize a novel compound P32 (5-(naphthalen-2-yl)-2-phenyl-4-(thiophen-2-ylmethyl)-2,4-dihydro-3H-pyrazol-3-one) as a potent mixed-competitive inhibitor of PL (IC50 =0.30 μM). In addition, P32 displayed some selectivity over other known serine hydrolases. A molecular docking study for P32 demonstrated that the inhibitory activity of P32 towards PL could be attributed to the π-π interactions of 2-naphthyl unit (R1 ) and hydrophobic interactions of phenyl moiety (R3 ) with the active site of PL. Thus, P32 could serve as promising lead compound for the development of more efficacious and selective pyrazolones-type PL inhibitors for biomedical applications.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  inhibitors; pancreatic lipases; pyrazolones; structure-activity relationships

Mesh:

Substances:

Year:  2021        PMID: 33527731     DOI: 10.1002/cmdc.202000850

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  1 in total

1.  Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1.

Authors:  Jing Zhang; Qiu-Sha Pan; Xing-Kai Qian; Xiang-Lu Zhou; Ya-Jie Wang; Rong-Jing He; Le-Tian Wang; Yan-Ran Li; Hong Huo; Cheng-Gong Sun; Lei Sun; Li-Wei Zou; Ling Yang
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.